LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Bicara Therapeutics Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERBCAX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / BCAX COVERAGE

What’s moving Bicara Therapeutics Inc. now

Current reporting with the operating signal separated from the noise.

01
Bicara Therapeutics Inc.: Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

Bicara Therapeutics Inc.: Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

The story matters when it changes Bicara Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

The story matters when it changes Bicara Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M ...

Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M ...

The story matters when it changes Bicara Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...

Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...

Investors are testing whether Bicara Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript

Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript

Investors are testing whether Bicara Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest BCAX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-11 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-10 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-30 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-28 · Period 2026-07-23SEC ↗8-KMaterial company eventFiled 2026-06-10 · Period 2026-06-09SEC ↗8-KMaterial company eventFiled 2026-05-21 · Period 2026-05-21SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-27 · Period 2026-04-21SEC ↗4Official SEC filingFiled 2026-07-29 · Period 2026-07-28SEC ↗
EARNINGS / QUARTERLY TRACKER

Bicara Therapeutics Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.